ライフサイエンスコーパス: dopamine receptor antagonist

1 opamine receptor agonist) and haloperidol (a dopamine receptor antagonist).

2 ncreases were not inhibited by a D1 subclass dopamine receptor antagonist.

3 oselective synthesis of (+)-sonepiprazole, a dopamine receptor antagonist.

4 mate receptor antagonist, or SCH 23390, a D1 dopamine receptor antagonist.

5 ion and depression-like symptoms, than other dopamine receptor antagonists.

6 nge alcohol drinking, and its sensitivity to dopamine receptor antagonists.

7 domisation was stratified by baseline use of dopamine receptor antagonists.

8 SCH 23390) or D2-like (100 microM sulpiride) dopamine receptor antagonists.

9 dopamine neuron stimulation and resistant to dopamine receptor antagonists.

10 phrenia have in common the property of being dopamine-receptor antagonists.

11 By administering the D2/D3 dopamine receptor antagonist [(11)C]raclopride at varyin

12 size DHCB and show that it displays moderate dopamine receptor antagonist activities.

13 Dopamine receptor antagonists also showed high affinity,

14 the effect of co-administering SCH23390 (D1 dopamine receptor antagonist) and quinpirole (D2 dopamin

15 SCH23390, a selective D(1) dopamine receptor antagonist, and (-)-butaclamol did not

16 A number of dopamine receptor antagonist/antipsychotic agents were s

17 bute to the pathophysiology of migraine, and dopamine receptor antagonists are prescribed in the trea

18 Novel dopamine receptor antagonists aripiprazole and ecopipam

19 Although a variety of dopamine receptor antagonists blocked cocaine self-admin

20 The binding of the fluorescent D1 dopamine receptor antagonist bodipy-SCH 23390 was measur

21 l history of tardive dystonia resulting from dopamine-receptor antagonist (DRA) treatment in 107 pati

22 Prolixin(R)) is a potent phenothiazine-based dopamine receptor antagonist, first introduced into clin

23 ion, was attenuated by pretreatment with the dopamine receptor antagonist, flupenthixol, into the cor

24 Both cis and trans isomers of the dopamine receptor antagonist flupentixol inhibit drug tr

25 f systemic administration of the nonspecific dopamine receptor antagonist flupentixol on response inv

26 intra-accumbens microinjection of either the dopamine receptor antagonist flupentixol or the nicotini

27 n determined; in addition, the effect of the dopamine receptor antagonist fluphenazine (0.1-1.0 mg/kg

28 Consistent with this notion, the D1/D2 dopamine receptor antagonist fluphenazine blocked footsh

29 induced rotational behavior was blocked by a dopamine receptor antagonist (fluphenazine).

30 Treatment of aged mutant mice with the dopamine receptor antagonist haloperidol precipitated mo

31 Pre-treatment with a dopamine receptor antagonist (haloperidol, 0.25 mg/kg; i

32 DISC was blocked by dopamine receptor antagonists (haloperidol, clozapine, e

33 After 7-day administration of the dopamine receptor antagonist, haloperidol (1 mg/kg), no

34 scimol was attenuated by administration of a dopamine receptor antagonist, haloperidol.

35 the increase in dopamine turnover and by the dopamine receptor antagonists, haloperidol, clozapine, a

36 iously, systemic administration of selective dopamine receptor antagonists has been shown to reduce a

37 Domperidone, a peripheral dopamine receptor antagonist, has been successfully used

38 ipsychotic potential of a highly specific D4 dopamine receptor antagonist (ie, L-745,870) in patients

39 Previous studies using dopamine receptor antagonists implicate the involvement

40 ng/ml PTX or with 1 microM L745,870, a D(4) dopamine receptor antagonist, indicating that activation

41 neous recording of neuronal firing and local dopamine receptor antagonist injection.

42 the nucleus accumbens core and infusion of a dopamine receptor antagonist into the contralateral dors

43 perant tasks and determined how injection of dopamine receptor antagonists into the accumbens influen

44 Like VTA baclofen injection, injection of dopamine receptor antagonists into the NAc profoundly re

45 The selective D4 dopamine receptor antagonist L-745,870 was ineffective a

46 This action of the dopamine receptor antagonists may contribute to their an

47 y D2 receptor blockade determines whether D2 dopamine receptor antagonist-mediated gene expression is

48 ors, hopes have run high that a selective D4 dopamine receptor antagonist might improve the pharmacol

49 -accumbens core flupenthixol, a nonselective dopamine receptor antagonist, on context renewal.

50 yperactivity was abolished by treatment with dopamine receptor antagonists or catecholamine biosynthe

51 Dopamine receptor antagonists or dopamine depletion fail

52 en injected systemically with flupentixol, a dopamine receptor antagonist, or vehicle before testing

53 nit activity was unaffected by D1 or D2-like dopamine-receptor antagonists, or by inhibition of evoke

54 s prolonged by perfusion of the selective D2 dopamine receptor antagonist raclopride (100 microM) int

55 ated ARS behavior, as did application of the dopamine receptor antagonist raclopride.

56 pical antipsychotic drug that is primarily a dopamine receptor antagonist, reduced 5-HT2C VNV isoform

57 Treatment with haloperidol, a D2 dopamine receptor antagonist, reduces this abnormal intr

58 ion of haloperidol (0.5 or 1.0 mg/kg, sc), a dopamine receptor antagonist, reversed both the behavior

59 bilateral intracranial injections of the D-1 dopamine receptor antagonist SCH 23390 HCl (0, 0.8, 1.6,

60 luence of bilateral VTA injections of the D1 dopamine receptor antagonist SCH 23390 or the 5-HT2 rece

61 In contrast, perfusion of the D1 dopamine receptor antagonist SCH-23390 (100 microM) did

62 hold was significantly increased by the D(1) dopamine receptor antagonist SCH23390 (10 microg kg(-1),

63 d persistent activity was enhanced by the D1 dopamine receptor antagonist SCH23390 [R(+)-7-chloro-8-h

64 t-LTP was completely blocked by the D1-like dopamine receptor antagonist SCH23390, but not by the D2

65 e, although, for a minority of units, the D1 dopamine-receptor antagonist SCH23390 attenuated neural

66 ed" methamphetamine seeking, using selective dopamine receptor antagonists (SCH39166 or raclopride) a

67 reatment of cells with 10 muM SCH23390, a D1 dopamine receptor antagonist, significantly inhibited th

68 electrophysiological action of droperidol, a dopamine receptor antagonist, since these cultures conta

69 Other dopamine receptor antagonists, spiperone and clozapine,

70 Tardive dyskinesia results from exposure to dopamine receptor antagonists, such as typical and atypi

71 and can be blocked in rats and monkeys with dopamine receptor antagonists, suggesting that increased

72 antagonist SCH23390, but not by the D2-like dopamine receptor antagonist sulpiride.

73 ts, whereas administration of D1- or D2-like dopamine receptor antagonists to further reduce dopamine

74 by measuring the ability of sulpiride, a D2 dopamine receptor antagonist, to increase the depolariza

75 Thus, infusing a dopamine receptor antagonist unilaterally into the basol

76 ed reinstatement by all compounds, whereas a dopamine receptor antagonist was effective only in block

77 A number of dopamine receptor antagonists were inverse agonists at D

78 dyskinetic clozapine (1) is a low-potency D2 dopamine receptor antagonist which appears to act select

79 se in the striatum, and haloperidol (hal), a dopamine receptor antagonist with high affinity for D2-l